No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 22 of the 40 quarters in the window, leaving 18 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:29.520Z. Latest historical point 2024-06-27. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Aethlon Medical, Inc. (AEMD) stock was $6.53 as of Oct 5, 2026, 4:00 PM EDT, up 1.16% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.2% · 3-year avg -78.8%/yr · 5-year avg -78.3%/yr
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States.
Medical - Devices · San Diego, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2014-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-2.91
Revenue Est.
N/A
Last Quarter Results
EPS
$-4.02
vs Estimate
$-3.92
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AEMD | $3.44M | $6.53 | +1.16% | -83.19% | -78.27% | -65.74% | N/A |
| 2ICCM | $3.47M | $1.54 | -1.91% | -94.60% | -63.05% | N/A | vs AEMD |
| 3EVGN | $3.48M | $0.40 | -4.99% | -64.71% | -56.46% | -39.70% | vs AEMD |
| 4CVKD | $3.37M | $0.95 | +0.60% | -93.24% | N/A | N/A | vs AEMD |
| 5EOCN | $3.59M | $3.45 | -4.43% | N/A | N/A | N/A | vs AEMD |
| 6ADGM | $3.13M | $0.14 | -7.84% | -92.86% | N/A | N/A | vs AEMD |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$13.25
+103.1% upside
Low
$1.50
Current
$6.53
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-3.38 | $-2.70 | $-2.01 | 2 |
| Quarter ending Dec 2026 | $-3.22 | $-1.71 | $-0.18 | 2 |
| Quarter ending Mar 2027 | $-1.14 | $-1.14 | $-1.14 | 1 |
| Quarter ending Jun 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-11.93 | $-6.49 | $-1.04 | 2 |
| FY 2028 | $-1.91 | $-1.91 | $-1.91 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2028 | $0.00 | $0.00 | $0.00 | 0 |
